Sirio Pharma (300791) — Cash Flow Quality Index
Latest as of June 2023:
1.42x
Sirio Pharma (300791) has a Cash Flow Quality Index of 1.42x as of June 2023. Operating cash flow of CN¥101.61 Million exceeds net income of CN¥71.79 Million, indicating high earnings quality where cash backs reported profits. Explore Sirio Pharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
1.42x
Operating CF / Net Income
Operating Cash Flow
CN¥101.61 Million
CNY
Net Income
CN¥71.79 Million
CNY
Data as of
Jun 2023
Most recent filing
Sirio Pharma Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Sirio Pharma across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Sirio Pharma cash flow conversion.
Annual Cash Flow Quality Index for Sirio Pharma (2016–2024)
Year-by-year earnings quality comparison for Sirio Pharma.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.74x | CN¥566.97 Million | CN¥325.06 Million | ▲ +27.0% |
| 2023 | 1.37x | CN¥386.08 Million | CN¥281.04 Million | ▼ -34.4% |
| 2022 | 2.10x | CN¥444.86 Million | CN¥212.29 Million | ▲ +42.3% |
| 2021 | 1.47x | CN¥341.38 Million | CN¥231.83 Million | ▲ +18.6% |
| 2020 | 1.24x | CN¥319.57 Million | CN¥257.37 Million | ▼ -23.6% |
| 2019 | 1.63x | CN¥231.60 Million | CN¥142.53 Million | ▲ +80.0% |
| 2018 | 0.90x | CN¥183.46 Million | CN¥203.23 Million | ▲ +90.8% |
| 2017 | 0.47x | CN¥49.35 Million | CN¥104.30 Million | ▲ +438.9% |
| 2016 | -0.14x | CN¥-98.26 Million | CN¥703.73 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.